Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AAV-mediated ARSA replacement for the treatment of Metachromatic Leukodystrophy

ABSTRACT: Metachromatic leukodystrophy (MLD) is an autosomal recessive neurodegenerative disorder caused by mutations in the arylsulfatase A (ARSA) gene, resulting in lower sulfatase activity and the toxic accumulation of sulfatides in the central and peripheral nervous system. Children account for 70% of cases and become progressively disabled with death occurring within 10 years of disease onset. Gene therapy approaches to restore ARSA expression via adeno- associated viral vectors (AAV) have been promising but hampered by limited brain biodistribution. We report the development of a novel capsid AAV.GMU01, demonstrating superior biodistribution and transgene expression in the central nervous system of non-human primates (NHPs). Next, we show that AAV.GMU01-ARSA treated MLD mice exhibit persistent, normal levels of sulfatase activity and a concomitant reduction in toxic sulfatides. Treated mice also show a reduction in MLD-associated pathology and auditory dysfunction. Lastly, we demonstrate that treatment with AAV.GMU01-ARSA in NHPs is well-tolerated and results in potentially therapeutic ARSA expression in the brain. In summary, we propose AAV.GMU01-ARSA mediated gene replacement as a clinically viable approach to achieve broad andvtherapeutic levels of ARSA.

ORGANISM(S): Mus musculus

PROVIDER: GSE299162 | GEO | 2025/06/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profile of patients affected by Metachromatic Leukodystrophy (MLD)

Project description:The genome-wide analysis of T lympocytes from 24 MLD patients and a corresponding number of matched controls reveals a list of differentially expressed genes that can be used to build classifiers that correctly classify not only patients and controls with high sensitivity and specificity, but also MLD patients into early- and late-onset clinical classes. Among the most differentially expressed genes, the class of metallothioneins shows a consistent and significant over-expression, confirmed also in affected tissues of patients and mouse models of MLD and other Lysosomal Storage Disorders, indicating metallothioneins a novel dynamic biomarker of disease progression and treatment response in this class of diseases. Moreover, gene onthology analysis performed on the microarray data suggest an involvement of stress response- and autophagy-related pathways as pathological mechanisms in MLD.

2013-11-21 | GSE23350 | GEO

Gene expression profile of patients affected by Metachromatic Leukodystrophy (MLD)

2013-11-21 | E-GEOD-23350 | biostudies-arrayexpress

Leukodystrophy-associated POLR3A mutations down-regulate the RNA polymerase III transcript and important regulatory RNA BC200

Project description:RNA polymerase III (Pol III) is an essential enzyme responsible for the synthesis of several small non-coding RNAs, a number of which are involved in mRNA translation. Recessive mutations in POLR3A, encoding the largest subunit of Pol III, cause POLR3-related hypomyelinating leukodystrophy (POLR3-HLD), characterized by deficient central nervous system myelination. Identification of the downstream effectors of pathogenic POLR3A mutations has been so far elusive. Here, we used CRISPR-Cas9 to introduce the POLR3A mutation c.2554A>G (p.M852V) into human cell lines and assessed its impact on Pol III biogenesis, nuclear import, DNA occupancy, transcription, and protein levels. Transcriptomic profiling uncovered a subset of transcripts vulnerable to Pol III hypofunction, including a global reduction in tRNA levels. The brain cytoplasmic BC200 RNA (BCYRN1), involved in translation regulation, was consistently affected in all our cellular models, including patient-derived fibroblasts. Genomic BC200 deletion in an oligodendroglial cell line led to major transcriptomic and proteomic changes, having a larger impact than those of POLR3A mutations. Upon differentiation, mRNA levels of the MBP gene, encoding myelin basic protein, were significantly decreased in POLR3A-mutant cells. Our findings provide the first evidence for impaired Pol III transcription in cellular models of POLR3-HLD and identify several candidate effectors, including BC200 RNA, having a potential role in oligodendrocyte biology and involvement in the disease.

2019-03-20 | GSE118739 | GEO

Data-independent Acquisition - Parallel Reaction Monitoring (DIA-PRM) Acquisition Reveals Alteration of Lysosomal Hydrolases in a Mouse Model of Metachromatic Leukodystrophy

Project description:For the reproducible analysis of peptides by mass spectrometry-based proteomics, data-independent acquisition (DIA) and parallel/multiple reaction monitoring (PRM/MRM) deliver unrivalled performance with respect to sensitivity and reproducibility. Both approaches come, however, with distinct advantages as well as shortcomings. While DIA enables the unbiased analysis of a large fraction of a sample’s proteome, it shows limitations with respect to dynamic range and the reproducible identification/quantification of low-abundant proteins. PRM, on the other hand, is ideally suited to reproducibly and sensitively quantify selected peptides originating from the proteins of interest, even if they are low-abundant, but no knowledge of the remaining sample is obtained. Here, we combine both methods into a mixed DIA-PRM acquisition approach, thereby merging the benefits of each method, while operating at reduced machine run times and sample amount, relative to individual measurements. We demonstrate the feasibility of the approach by merging a scheduled PRM assay for 59 low-abundant lysosomal hydrolases, covered through 103 peptides, with a DIA data acquisition scheme. After benchmarking DIA-PRM against mouse embryonic fibroblast (MEF) whole cell lysates, we use the approach to investigate disease progression in brain tissues of a mouse model of metachromatic leukodystrophy (MLD). In these tissues, we found a progressive increase in lysosomal hydrolases in MLD as compared to healthy control mice .

2025-05-07 | PXD052313 | Pride

Homo sapiens

Project description:Gene expression profile of patients affected by Metachromatic Leukodystrophy (MLD)

| PRJNA131461 | ENA

Proteosome inhibitor repurposing rescues hypomyelination in HIKESHI-associated Leukodystrophy

Project description:Proteosome inhibitor repurposing rescues hypomyelination in HIKESHI-associated Leukodystrophy

| PRJNA1380631 | ENA

Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III

Project description:A small proportion of 4H (Hypomyelination, Hypodontia and Hypogonadotropic Hypogonadism) or RNA polymerase III (POLR3)-related leukodystrophy cases are negative for mutations in the previously identified causative genes POLR3A and POLR3B. Here, we report eight of these cases carrying recessive mutations in POLR1C, a gene encoding a shared POLR1 and POLR3 subunit, also mutated in some Treacher Collins syndrome (TCS) cases. Using shotgun proteomics and ChIP-sequencing we demonstrate that leukodystrophy causative mutations, but not TCS mutations, in POLR1C impair assembly and nuclear import of POLR3, but not POLR1, leading to decreased binding to POLR3 target genes. This study is the first to show that distinct mutations in a gene coding for a shared subunit of two RNA polymerases lead to selective modification of the enzymes' availability leading to two different clinical conditions and to shed some light on the pathophysiological mechanism of one of the most common hypomyelinating leukodystrophies, POLR3-related leukodystrophy.

2019-10-16 | PXD002154 | Pride

Proteosome inhibitor repurposing rescues hypomyelination in HIKESHI-associated Leukodystrophy

Project description:HIKESHI-associated leukodystrophy (HAL) is a lethal genetic neurological condition with most patients dying in childhood. HAL is caused by homozygous mutations in the HIKESHI gene leading to protein loss. HIKESHI serves as a nuclear import carrier for chaperone HSP70 during heat shock response (HSR). As the primary abnormalities are related to white matter, we geneated iPSCs from affected homozygous HAL patients, non-symptomatic heterozygous first-degree relatives, and healthy unrelated individuals. iPSCs were differentiated into oligodendrocytes, followed by immunofluorescent staining and various assays. Bulk RNASeq revealed various upregulated and downregulated genes during oligodendrocyte development. Immunofluorescence indicates HSP70 and other proteins displayed altered nuclear localization in HIKESHI homozygous cells. Homozygous cells also had much fewer Olig2+ cells, aberrant myelination, and misshapen cells. We conclude that loss of HIKESHI results in dysfunction of oligodendrocyte development and function.

2026-03-12 | GSE313678 | GEO

AAV-mediated ARSA replacement for the treatment of Metachromatic Leukodystrophy

Project description:AAV-mediated ARSA replacement for the treatment of Metachromatic Leukodystrophy

| PRJNA1273005 | ENA

A mouse model of Free Sialic Acid Storage Disorder: Hypomyelinating leukodystrophy and Purkinje cell degeneration

Project description:Free sialic acid storage disorder (FSASD) is a rare, neurodegenerative lysosomal storage disease caused by biallelic variants in SLC17A5, which encodes the lysosomal sialic acid exporter sialin. Although clinical severity varies, all affected individuals exhibit progressive neurological decline and characteristic lysosomal and urinary accumulation of free sialic acid, and no FDA-approved therapies currently exist, with the molecular basis of central nervous system dysfunction remaining poorly defined. To model the most prevalent disease-associated allele, a Slc17a5R39C mouse carrying the pathogenic p.Arg39Cys variant was generated using CRISPR/Cpf1. Homozygous Slc17a5R39C/R39C mice recapitulate key features of FSASD, including biochemical accumulation of free sialic acid, progressive ataxia, tremors, seizures, and reduced lifespan. Neuropathological analyses demonstrate widespread central nervous system hypomyelination with relative preservation of peripheral myelination, while transcriptomic profiling reveals broad suppression of myelin-associated genes alongside a cerebellum-specific inflammatory signature. These changes are accompanied by marked astrogliosis, progressive Purkinje cell degeneration, and increased neurofilament proteins, including serum NfL. Collectively, the Slc17a5R39C/R39C model provides critical insight into disease pathogenesis, highlights region-specific neurodegenerative vulnerability, and establishes a robust preclinical platform for mechanistic and therapeutic studies.

2026-04-30 | GSE328153 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data